{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:09:30Z","timestamp":1789463370473,"version":"build-2803163510"},"reference-count":118,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Anti-CD19 CAR T-cell therapy has produced major advances in treating hematologic malignancies. Recently, researchers have explored its use in autoimmune diseases. However, the complex pathogenesis and high heterogeneity of these disorders create substantial uncertainty about treatment efficacy and safety in clinical settings. Quantitative systems pharmacology (QSP) models integrate multiple pathophysiological mechanisms and map real patients onto virtual \u201cdigital twins\u201d to simulate the\n                    <jats:italic>in vivo<\/jats:italic>\n                    behavior of a given CAR T-cell dose after infusion and to predict benefits and risks. Such models can also inform optimization of infusion dosing, advancing personalized therapy. This review summarizes current applications of anti-CD19 CAR T cells in autoimmune diseases and surveys the state of quantitative mathematical modeling in the field. Building on existing models, we propose an idealized QSP framework intended to guide the development of more refined, actionable models.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1823722","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:10:04Z","timestamp":1789459804000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-CD19 CAR T-cell therapy for autoimmune diseases: from exploratory clinical trials to quantitative pharmacodynamic modeling development"],"prefix":"10.3389","volume":"17","author":[{"given":"Yuqin","family":"Sun","sequence":"first","affiliation":[{"name":"The First Clinical College, Xuzhou Medical University","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Heng","sequence":"additional","affiliation":[{"name":"The First Clinical College, Xuzhou Medical University","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Hu","sequence":"additional","affiliation":[{"name":"Nanjing IASO Biotherapeutics Co Ltd","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiumei","family":"Bo","sequence":"additional","affiliation":[{"name":"National Demonstration Center for Experimental Basic Medical Science Education, Xuzhou Medical University","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41573-024-01016-0","article-title":"Author correction: Sequential immunotherapy: towards cures for autoimmunity","volume":"23","author":"Ram\u00edrez-Valle","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1647066","article-title":"Innovations in immunotherapy for autoimmune diseases: recent breakthroughs and future directions","volume":"16","author":"Alsayb","year":"2025","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1613878","article-title":"CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon","volume":"16","author":"Wu","year":"2025","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric antigen receptor T cell therapy for autoimmune disease","volume":"24","author":"Chung","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell Malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-025-00085-z","article-title":"The race to reset autoimmune diseases","volume":"24","author":"Bhandari","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"B8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.clicom.2025.09.003","article-title":"Reprogramming immunity: Emerging therapeutic frontiers and clinical trial advances of CAR-T cell therapy in autoimmune diseases","volume":"8","author":"Mukherjee","year":"2025","journal-title":"Clin Immunol Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1533254","article-title":"Advance in chimeric antigen receptor T therapy in autoimmune diseases","volume":"16","author":"Ji","year":"2025","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04191-8","article-title":"Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases","volume":"32","author":"Becilli","year":"2026","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12974-025-03668-0","article-title":"CAR T cells as novel therapeutic strategy for multiple sclerosis and other neuroimmune disorders","volume":"23","author":"Samadzadeh","year":"2025","journal-title":"J Neuroinflamm"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-01687-x","article-title":"Deconvolution of clinical variance in CAR-T cell pharmacology and response","volume":"41","author":"Kirouac","year":"2023","journal-title":"Nat Biotechnol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41540-024-00355-3","article-title":"Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics","volume":"10","author":"Kirouac","year":"2024","journal-title":"NPJ Syst Biol Appl"},{"key":"B15","doi-asserted-by":"publisher","first-page":"4819","DOI":"10.1038\/s41467-025-59904-x","article-title":"Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoire","volume":"16","author":"Cheloni","year":"2025","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00420","article-title":"Precision dosing priority criteria: Drug, disease, and patient population variables","volume":"11","author":"Tyson","year":"2020","journal-title":"Front Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.693016","article-title":"CAR-T cell therapy: Mechanism, management, and mitigation of inflammatory toxicities","volume":"12","author":"Fischer","year":"2021","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-025-02662-7","article-title":"Optimization of CAR T-cell dose: a debated unresolved issue","volume":"60","author":"Bouzianas","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"B19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-024-01065-z","article-title":"Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients","volume":"14","author":"Mart\u00edn-Mart\u00edn","year":"2024","journal-title":"Blood Cancer J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41540-025-00544-8","article-title":"QSP modeling of loncastuximab tesirine with T-cell-dependent bispecific antibodies guides dose-regimen strategy","volume":"11","author":"Li","year":"2025","journal-title":"NPJ Syst Biol Appl"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41467-025-68272-5","article-title":"AI-guided CAR designs and targeted pathway modulation to enhance multi-antigen CAR T cell durability and overcome antigen escape","volume":"17","author":"Ansari","year":"2026","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/ni1547","article-title":"CD19 is essential for B cell activation by promoting B cell receptor\u2013antigen microcluster formation in response to membrane-bound ligand","volume":"9","author":"Depoil","year":"2008","journal-title":"Nat Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0615-5","article-title":"CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives","volume":"33","author":"Mohty","year":"2019","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"13921","DOI":"10.1038\/s41598-017-14089-2","article-title":"Peripheral CD19hi B cells exhibit activated phenotype and functionality in promoting IgG and IgM production in human autoimmune diseases","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1502712","article-title":"CD19 CAR-T cell therapy: a new dawn for autoimmune rheumatic diseases","volume":"15","author":"Rangel-Pel\u00e1ez","year":"2024","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-025-01349-4","article-title":"Roads and detours for CAR T cell therapy in autoimmune diseases","volume":"25","author":"Avouac","year":"2026","journal-title":"Nat Rev Drug Discov"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheumatic Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"IJMS"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines14020296","article-title":"CAR T-cell immunotherapy in neuroautoimmune diseases: Focus on the central nervous system","volume":"14","author":"Demetriou","year":"2026","journal-title":"Biomedicines"},{"key":"B32","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s41392-025-02415-4","article-title":"Multiple sclerosis: molecular pathogenesis and therapeutic intervention","volume":"10","author":"Boutitah-Benyaich","year":"2025","journal-title":"Sig Transduct Target Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.34133\/research.0712","article-title":"Revolutionizing autoimmune kidney disease treatment with chimeric antigen receptor-T cell therapy","volume":"8","author":"Gu","year":"2025","journal-title":"Research"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103229","article-title":"Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Shu","year":"2025","journal-title":"eClinicalMedicine"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-025-01128-1","article-title":"Allogeneic anti-CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus","volume":"35","author":"Yang","year":"2025","journal-title":"Cell Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101794","article-title":"Anti-CD19 CAR-T cells are effective in severe idiopathic Lambert-Eaton myasthenic syndrome","volume":"5","author":"Wickel","year":"2024","journal-title":"Cell Rep Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103692","article-title":"Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cells","volume":"24","author":"He","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B39","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/art.42784","article-title":"CD19 chimeric antigen receptor T cell treatment: Unraveling the role of B cells in systemic lupus erythematosus","volume":"76","author":"Taubmann","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2403227121","article-title":"Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome","volume":"121","author":"Faissner","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00375-7","article-title":"Anti-CD19 CAR T cells for refractory myasthenia gravis","volume":"22","author":"Haghikia","year":"2023","journal-title":"Lancet Neurol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/art.42933","article-title":"Autologous CD19\u2010targeting CAR T cells in a patient with refractory juvenile dermatomyositis","volume":"76","author":"Nicolai","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheumatic Dis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease \u2014 a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04185-6","article-title":"CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1\/2 CASTLE basket trial","volume":"32","author":"M\u00fcller","year":"2026","journal-title":"Nat Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2008.08.003","article-title":"Role of B cells in systemic lupus erythematosus and rheumatoid arthritis","volume":"20","author":"Mandik-Nayak","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41392-025-02510-6","article-title":"Anti-BCMA CAR-T cells attenuate microglial activation in progressive multiple sclerosis: indicating a plasma cell-microglia crosstalk","volume":"10","author":"Ismail","year":"2025","journal-title":"Sig Transduct Target Ther"},{"key":"B49","unstructured":"Efficacy and safety of BMS-986353, a CD19-directed chimeric antigen receptor T cell therapy manufactured using a next-generation process: Updated data from a phase 1 trial in patients with systemic sclerosis\n          \n          \n            \n              Khanna\n              D\n            \n            \n              Korman\n              D\n            \n            \n              Bernstein\n              E\n            \n            \n              Kramer\n              N\n            \n            \n              Majithia\n              V\n            \n            \n              Mease\n              P\n            \n          \n          \n          2025"},{"key":"B50","unstructured":"Promising early outcomes with BMS-986353, a CD19-directed chimeric antigen receptor T cell therapy in severe refractory idiopathic inflammatory myopathies: Safety and efficacy findings from the ongoing phase 1 trial\n          \n          \n            \n              Aggarwal\n              R\n            \n            \n              Korman\n              D\n            \n            \n              Wiesendanger\n              M\n            \n            \n              Majithia\n              V\n            \n            \n              De Langhe\n              E\n            \n            \n              Schmalzing\n              M\n            \n          \n          \n          2025"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1630569","article-title":"CAR-T cell therapies in autoimmune rheumatic diseases: a brief report on the clinical trial landscape, current status, and future perspectives","volume":"16","author":"Xu","year":"2025","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103350","article-title":"Advances in chimeric antigen receptor T cell therapy for autoimmune and autoinflammatory diseases and their complications","volume":"150","author":"Zeng","year":"2025","journal-title":"J Autoimmun"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103495","article-title":"Chimeric antigen receptor T cell therapy: a new frontier therapeutic landscape in autoimmune diseases","volume":"157","author":"An","year":"2025","journal-title":"J Autoimmun"},{"key":"B54","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00281-024-01019-4","article-title":"Advances in manufacturing chimeric antigen receptor immune cell therapies","volume":"46","author":"Ramamurthy","year":"2024","journal-title":"Semin Immunopathol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100778","article-title":"Allogeneic CAR-T cells in lupus: Bridging the gap for a new therapeutic era","volume":"6","author":"Orofino","year":"2025","journal-title":"Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2021.0087","article-title":"Focused evaluation of the roles of macrophages in chimeric antigen receptor (CAR) T cell therapy associated cytokine release syndrome","volume":"18","author":"Guo","year":"2021","journal-title":"Cancer Biol Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-025-03711-8","article-title":"Chimeric antigen receptor (CAR) therapies for precise eradication of pathogenic cells in autoimmunity","volume":"28","author":"Kalliolias","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"B58","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10238-026-02076-9","article-title":"CAR-T therapy for autoimmune rheumatic diseases: navigating clinical frontiers between breakthroughs and uncertainties","volume":"26","author":"Cheng","year":"2026","journal-title":"Clin Exp Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(25)00091-8","article-title":"Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study","volume":"7","author":"Hagen","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ado2084","article-title":"Engineering CAR-T therapies for autoimmune disease and beyond","volume":"16","author":"English","year":"2024","journal-title":"Sci Transl Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and new technologies in adoptive cell therapy","volume":"16","author":"Zhang","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103859","article-title":"Chimeric antigen receptor cell therapy: A revolutionary approach transforming cancer treatment to autoimmune disease therapy","volume":"24","author":"Wen","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1465191","article-title":"Application of novel CAR technologies to improve treatment of autoimmune disease","volume":"15","author":"Cheever","year":"2024","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3703","article-title":"FDA experience on CAR T cell pharmacokinetics\/pharmacodynamics and model\u2010Based assessments","volume":"118","author":"Tegenge","year":"2025","journal-title":"Clin Pharma Ther"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012331","article-title":"Mechanistic data-informed multiscale quantitative systems pharmacology modeling framework enables the clinical translation and efficacy assessment of CAR-T therapy in solid tumors","volume":"13","author":"Yang","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005360","article-title":"Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse","volume":"10","author":"Liu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B67","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12016-025-09114-6","article-title":"Chimeric antigen receptor T cell therapy in systemic lupus erythematosus: mechanisms, clinical advances, and future directions a comprehensive review","volume":"68","author":"Matarneh","year":"2025","journal-title":"Clinic Rev Allerg Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1714438","article-title":"Conceptual quantitative systems pharmacology framework for supporting clinical trial design in organ-specific autoimmune and rare diseases","volume":"16","author":"Sun","year":"2025","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s10238-025-02014-1","article-title":"Refractory lupus nephritis: current Understanding and emerging treatment strategies","volume":"26","author":"Ding","year":"2025","journal-title":"Clin Exp Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20240499","article-title":"CD19-directed T cell\u2013engaging antibodies for the treatment of autoimmune disease","volume":"221","author":"Michaelson","year":"2024","journal-title":"J Exp Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01769-0","article-title":"Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases","volume":"19","author":"Chen","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1987","article-title":"Quantitative systems pharmacology approaches for immuno\u2010Oncology: adding virtual patients to the development paradigm","volume":"109","author":"Chelliah","year":"2021","journal-title":"Clin Pharma Ther"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1012908","article-title":"Mathematical modeling unveils the timeline of CAR-T cell therapy and macrophage-mediated cytokine release syndrome","volume":"21","author":"Santurio","year":"2025","journal-title":"PloS Comput Biol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1688616","article-title":"Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model","volume":"12","author":"Singh","year":"2020","journal-title":"mAbs"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12598","article-title":"Bench\u2010to\u2010bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic\u2010pharmacodynamic model: A case study with anti\u2010BCMA CAR\u2010T","volume":"10","author":"Singh","year":"2021","journal-title":"CPT Pharmacom Syst Pharma"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fsysb.2024.1380018","article-title":"A multi-scale semi-mechanistic CK\/PD model for CAR T-cell therapy","volume":"4","author":"Minucci","year":"2024","journal-title":"Front Syst Biol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltaf001","article-title":"Applying population mechanistic modelling to find determinants of chimeric antigen receptor T-cells dynamics in month-one lymphoma patients","volume":"5","author":"Brown","year":"2024","journal-title":"Immunotherapy Adv"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13259","article-title":"Quantitative pharmacology of dual\u2010targeted bicistronic CAR \u2010T\u2010cell therapy using multiscale mechanistic modeling","volume":"14","author":"Su","year":"2025","journal-title":"CPT Pharmacom Syst Pharma"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70146","article-title":"Mechanistic evaluation of anti\u2010 CD19 CAR \u2010T cell therapy repurposed in systemic lupus erythematosus using a quantitative systems pharmacology model","volume":"18","author":"Park","year":"2025","journal-title":"Clin Trans Sci"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16623","article-title":"Efficacy and safety of humanized anti\u2010CD19\u2010CAR\u2010T therapy following intensive lymphodepleting chemotherapy for refractory\/relapsed B acute lymphoblastic leukaemia","volume":"191","author":"Wang","year":"2020","journal-title":"Br J Haematol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1303935","article-title":"Lymphodepletion \u2013 an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle","volume":"14","author":"Lickefett","year":"2023","journal-title":"Front Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00436","article-title":"Stochastic inheritance of division and death times determines the size and phenotype of CD8+ T cell families","volume":"10","author":"Pandit","year":"2019","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2315990121","article-title":"Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy","volume":"121","author":"Qin","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01224-z","article-title":"Epigenetic regulation of T cell exhaustion","volume":"23","author":"Belk","year":"2022","journal-title":"Nat Immunol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00281-025-01065-6","article-title":"Systemic sclerosis: pathogenic mechanisms and their implications for treatment","volume":"47","author":"Lescoat","year":"2025","journal-title":"Semin Immunopathol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1002\/art.41927","article-title":"Defective early B cell tolerance checkpoints in patients with systemic sclerosis allow the production of self antigen \u2013specific clones","volume":"74","author":"Glauzy","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/art.41243","article-title":"Profibrotic activation of human macrophages in systemic sclerosis","volume":"72","author":"Bhandari","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3390\/cells10051104","article-title":"Cytokines involved in the pathogenesis of SSc and problems in the development of anti-cytokine therapy","volume":"10","author":"Shima","year":"2021","journal-title":"Cells"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11782","article-title":"Impact of scleroderma\u2010Associated autoantibodies on clinical outcome assessments: post hoc analysis from a randomised, double\u2010blind, placebo\u2010controlled, phase 3 trial of tocilizumab in scleroderma","volume":"7","author":"Al Dulaijan","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s13075-020-02329-2","article-title":"Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database","volume":"22","author":"Allanore","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clinic Rev Allerg Immunol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/ar2501","article-title":"Developments in the scientific and clinical understanding of inflammatory myopathies","volume":"10","author":"Lundberg","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.5692\/clinicalneurol.54.1113","article-title":"Pathological features of myositis with myositis -specific autoantibodies","volume":"54","author":"Shimizu","year":"2014","journal-title":"Rinsho Shinkeigaku"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3390\/ijms160818683","article-title":"Scanning for therapeutic targets within the cytokine network of idiopathic inflammatory myopathies","volume":"16","author":"De Paepe","year":"2015","journal-title":"IJMS"},{"key":"B95","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/rheumatology\/keg427","article-title":"International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease","volume":"43","author":"Isenberg","year":"2004","journal-title":"Rheumatology"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20532","article-title":"Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient\/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)\/Childhood Health Assessment Questionnaire (C\u2010HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF\u201036), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index\u20102 (FI\u20102), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI)","volume":"63","author":"Rider","year":"2011","journal-title":"Arthritis Care Res"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez423","article-title":"How rheumatologists assess disability in the current era needs an overhaul: focus on the Health Assessment Questionnaire","volume":"59","author":"Bukhari","year":"2020","journal-title":"Rheumatology"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.079830","article-title":"Amplifying elements of arthritis and joint destruction","volume":"66","author":"Van Den Berg","year":"2007","journal-title":"Ann Rheumatic Dis"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2010.22","article-title":"The cytokine milieu in the interplay of pathogenic Th1\/Th17 cells and regulatory T cells in autoimmune disease","volume":"7","author":"Leung","year":"2010","journal-title":"Cell Mol Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222010922","article-title":"Cytokine networks in the pathogenesis of rheumatoid arthritis","volume":"22","author":"Kondo","year":"2021","journal-title":"IJMS"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584","article-title":"Rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheumatism"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00646.x","article-title":"B\u2010lymphocyte contributions to human autoimmune disease","volume":"223","author":"Yanaba","year":"2008","journal-title":"Immunol Rev"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing\u2013remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"B104","doi-asserted-by":"publisher","first-page":"310ra166","DOI":"10.1126\/scitranslmed.aab4176","article-title":"Proinflammatory GM-CSF\u2013producing B cells in multiple sclerosis and B cell depletion therapy","volume":"7","author":"Li","year":"2015","journal-title":"Sci Transl Med"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000431","article-title":"Proinflammatory B-cell profile in the early phases of MS predicts an active disease","volume":"5","author":"Guerrier","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2015.173","article-title":"Body fluid biomarkers for multiple sclerosis\u2014the long road to clinical application","volume":"11","author":"Teunissen","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000156155.19270.F8","article-title":"Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity","volume":"64","author":"Roxburgh","year":"2005","journal-title":"Neurology"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004727","article-title":"Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel","volume":"10","author":"Szabo","year":"2024","journal-title":"RMD Open"},{"key":"B110","doi-asserted-by":"publisher","first-page":"6414","DOI":"10.1016\/j.cell.2025.09.020","article-title":"Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis","volume":"188","author":"Qin","year":"2025","journal-title":"Cell"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1450173","article-title":"Identification of early predictive biomarkers for severe cytokine release syndrome in pediatric patients with chimeric antigen receptor T-cell therapy","volume":"15","author":"Su","year":"2024","journal-title":"Front Immunol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-026-01386-y","article-title":"TWEAK receptor (Fn14) exacerbates TNF-\u03b1-induced inflammation in rheumatoid arthritis synovial fibroblasts and influences response to anti-TNF-\u03b1 therapy","volume":"23","author":"Shaikh","year":"2026","journal-title":"Cell Mol Immunol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adx7845","article-title":"Armored human CAR Treg cells with PD1 promoter-driven IL-10 have enhanced suppressive function","volume":"11","author":"Boardman","year":"2025","journal-title":"Sci Adv"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2026.02.001","article-title":"CAR-mediated release of IL-10 increases the function of regulatory T cells: relevance for future clinical application","volume":"34","author":"Saleem","year":"2026","journal-title":"Mol Ther"},{"key":"B115","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s42003-026-09528-8","article-title":"IL-15 overexpression promotes memory program and anti-tumor activity of CD64 CAR T cells in a preclinical AML model","volume":"9","author":"Shan","year":"2026","journal-title":"Commun Biol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3390\/cells15060547","article-title":"Empowerment of CAR-T cells by IL-7 and IL-15 boosts their efficacy against HER2-positive tumors with enhanced expansion and persistence","volume":"15","author":"Cheng","year":"2026","journal-title":"Cells"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aec2632","article-title":"IL-7\/IL-15\/IL-21 cytokine-fusion scaffold generates highly functional CAR T cells enriched in long-lived T memory stem cells","volume":"12","author":"Cole","year":"2026","journal-title":"Sci Adv"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1823722\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:10:08Z","timestamp":1789459808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1823722\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":118,"alternative-id":["10.3389\/fimmu.2026.1823722"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1823722","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"1823722"}}